Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Receivables (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Change in Receivables for 6 consecutive years, with $501000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables rose 749.15% to $501000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $746000.0, a 230.09% increase, with the full-year FY2024 number at $228000.0, up 189.41% from a year prior.
  • Change in Receivables was $501000.0 for Q3 2025 at Vivos Therapeutics, up from -$19000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.8 million in Q2 2021 to a low of -$2.6 million in Q4 2021.
  • A 5-year average of -$12157.9 and a median of -$19000.0 in 2025 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 4626.55% in 2021, then tumbled 2283.33% in 2024.
  • Vivos Therapeutics' Change in Receivables stood at -$2.6 million in 2021, then soared by 84.45% to -$409000.0 in 2022, then surged by 93.64% to -$26000.0 in 2023, then rose by 7.69% to -$24000.0 in 2024, then skyrocketed by 2187.5% to $501000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Change in Receivables are $501000.0 (Q3 2025), -$19000.0 (Q2 2025), and $288000.0 (Q1 2025).